ES2958412T3 - Cerdulatinib para el tratamiento de tumores malignos de linfocitos B - Google Patents
Cerdulatinib para el tratamiento de tumores malignos de linfocitos B Download PDFInfo
- Publication number
- ES2958412T3 ES2958412T3 ES16804177T ES16804177T ES2958412T3 ES 2958412 T3 ES2958412 T3 ES 2958412T3 ES 16804177 T ES16804177 T ES 16804177T ES 16804177 T ES16804177 T ES 16804177T ES 2958412 T3 ES2958412 T3 ES 2958412T3
- Authority
- ES
- Spain
- Prior art keywords
- cerdulatinib
- pharmaceutically acceptable
- acceptable salt
- patient
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168530P | 2015-05-29 | 2015-05-29 | |
| US201562263582P | 2015-12-04 | 2015-12-04 | |
| PCT/US2016/034861 WO2016196385A1 (en) | 2015-05-29 | 2016-05-27 | Cerdulatinib for the treatment of b-cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2958412T3 true ES2958412T3 (es) | 2024-02-08 |
Family
ID=57441822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16804177T Active ES2958412T3 (es) | 2015-05-29 | 2016-05-27 | Cerdulatinib para el tratamiento de tumores malignos de linfocitos B |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180147203A1 (enExample) |
| EP (1) | EP3302485B1 (enExample) |
| JP (2) | JP7258462B2 (enExample) |
| KR (1) | KR102613106B1 (enExample) |
| CN (1) | CN107683139A (enExample) |
| AU (1) | AU2016270658B2 (enExample) |
| CA (1) | CA2987324C (enExample) |
| ES (1) | ES2958412T3 (enExample) |
| WO (1) | WO2016196385A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6833816B2 (ja) | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| CA2950640A1 (en) | 2015-12-04 | 2017-06-04 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
| US20180065317A1 (en) | 2016-09-06 | 2018-03-08 | Cc3D Llc | Additive manufacturing system having in-situ fiber splicing |
| WO2018189566A1 (en) * | 2017-04-10 | 2018-10-18 | Dorian Bevec | Use of a chemical compound as a therapeutic agent |
| JP2021523114A (ja) * | 2018-05-04 | 2021-09-02 | ポートラ ファーマシューティカルズ， インコーポレイテッド | リンパ腫の治療方法 |
| US10865198B2 (en) | 2018-05-04 | 2020-12-15 | Alexion Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255756A (ja) | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| WO1999031073A1 (en) | 1997-12-15 | 1999-06-24 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| WO2003037352A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| JP2009544592A (ja) | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物 |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| CA2960692C (en) | 2008-04-16 | 2019-09-24 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
| EP2621489A1 (en) * | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| CA2844507A1 (en) * | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
| JP2015522091A (ja) * | 2012-06-27 | 2015-08-03 | ノボマー， インコーポレイテッド | ポリエステル生成のための触媒および方法 |
| BR112015001690A2 (pt) * | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
| CA2890111A1 (en) | 2012-11-02 | 2014-05-08 | Pharmacyclics, Inc. | Tec family kinase inhibitor adjuvant therapy |
| CN105282602A (zh) * | 2014-07-07 | 2016-01-27 | 乐视致新电子科技（天津）有限公司 | 数据处理方法、装置及移动终端设备 |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| JP6833816B2 (ja) | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| CA2950640A1 (en) * | 2015-12-04 | 2017-06-04 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
-
2016
- 2016-05-27 JP JP2017561821A patent/JP7258462B2/ja active Active
- 2016-05-27 CN CN201680035029.0A patent/CN107683139A/zh active Pending
- 2016-05-27 EP EP16804177.0A patent/EP3302485B1/en active Active
- 2016-05-27 KR KR1020177036772A patent/KR102613106B1/ko active Active
- 2016-05-27 WO PCT/US2016/034861 patent/WO2016196385A1/en not_active Ceased
- 2016-05-27 AU AU2016270658A patent/AU2016270658B2/en active Active
- 2016-05-27 ES ES16804177T patent/ES2958412T3/es active Active
- 2016-05-27 US US15/578,190 patent/US20180147203A1/en not_active Abandoned
- 2016-05-27 CA CA2987324A patent/CA2987324C/en active Active
-
2021
- 2021-05-10 US US17/316,530 patent/US12350269B2/en active Active
- 2021-06-30 JP JP2021108659A patent/JP2021152076A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016270658A1 (en) | 2018-01-04 |
| AU2016270658B2 (en) | 2021-08-12 |
| CA2987324C (en) | 2023-08-22 |
| US20220096471A1 (en) | 2022-03-31 |
| WO2016196385A1 (en) | 2016-12-08 |
| JP2021152076A (ja) | 2021-09-30 |
| US12350269B2 (en) | 2025-07-08 |
| JP7258462B2 (ja) | 2023-04-17 |
| EP3302485B1 (en) | 2023-07-12 |
| KR20180011210A (ko) | 2018-01-31 |
| CA2987324A1 (en) | 2016-12-08 |
| EP3302485A4 (en) | 2019-02-27 |
| US20180147203A1 (en) | 2018-05-31 |
| KR102613106B1 (ko) | 2023-12-12 |
| EP3302485A1 (en) | 2018-04-11 |
| JP2018520117A (ja) | 2018-07-26 |
| CN107683139A (zh) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2958412T3 (es) | Cerdulatinib para el tratamiento de tumores malignos de linfocitos B | |
| US11446300B2 (en) | Cerdulatinib for treating hematological cancers | |
| ES2863996T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CN102427814A (zh) | 激酶蛋白结合抑制剂 | |
| BR112019017851A2 (pt) | método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo | |
| JP2019511204A (ja) | コパンリシブバイオマーカー | |
| JP2019512003A (ja) | コパンリシブバイオマーカー | |
| BR112020022430A2 (pt) | métodos para tratamento de linfoma | |
| Zhang et al. | Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma | |
| HK1253804A1 (en) | Cerdulatinib for the treatment of b-cell malignancies | |
| HK1253804B (en) | Cerdulatinib for the treatment of b-cell malignancies | |
| HK1262118A1 (en) | Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma | |
| HK1262118B (en) | Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma | |
| HK40000537A (en) | Copanlisib biomarkers |